Theoretical Medicine (Poster discussion will take place on the terrace of the room during the Coffee Break)
Introduction: Modulated electro-hyperthermia (mEHT) is an advanced option in the hyperthermia field, applying 13.56 Radiofrequency electromagnetic current to induce tumor-specific damage. Lyso-thermosensitive Liposomal Doxorubicin (LTLD) offers a promising approach to improve efficacy and reduce systematic toxicity of DOX.
Aims: check the efficacy and toxicity of LTLD+ mEHT combination
Methods: Triple-negative breast cancer cell line (4T1), was orthotopically injected into Balb/C mice and treated with LTLD (ThermoDox (Ceslion)). Tumor growth inhibition was followed and Dox concentration in the tumors was measured by spectrophotometry. Body weight, cardiac function and hematology were evaluated.
Results:
LTLD+ mEHT combination was significantly the most effective in tumor growth inhibition compared to DOX+ mEHT as demonstrated by both tumor volume and tumor weight reduction (tumor weight, LTLD+mEHT: 113.3±46.71mg vs DOX+mEHT: 170±51.43mg) (P=0.05). Moreover, the highest tumor destruction ratio (TDR) was observed in (LTLD+mEHT) group on HE stained samples (LTLD+mEHT:73.5±18.49%, DOX+mEHT: 61±15.38%, mEHT: 46.13±18.8%, DOX: 36.56±12.32%, sham:43.63±14.23%). Body weight loss was the strongest in the DOX+mEHT treated mice. LTLD reduced body weight loss significantly (LTLD+mEHT: 14.55± 4.66% vs DOX+ mEHT: 20.01± 3.65%) (P=0.02).
Conclusion:
mEHT can be an effective approach to deliver DOX-encapsulated in LTLD into TNBC tumors with a better safety profile.
Funding: EFOP-3.6.3-VEKOP-16-2017-00009